Will Biden’s American Families Plan Include an Rx Drug Pricing Measure?

There is a rift between President Biden and House Democrats over whether to include provisions to lower drug prices in his American Families plan, or deal with drug pricing later in another bill. | Official White House Photo by Adam Schultz

President Biden might exclude legislation to reduce what consumers and the federal government pay for prescription drugs from his American Families human and capital investment initiative, news organizations report this morning. Biden is scheduled to describe his infrastructure investment plan

Read More »

340B Providers Escape Bullet in House Dem Rx Bill, but Not in GOP Version

U.S. House E&C Chair Frank Pallone this morning re-introduced a major drug pricing bill from the last session of Congress, minus language from last year's version strongly opposed by 340b covered entities. | C-SPAN

UPDATE Thursday, April 22, 2021, 1:00 p.m. EDT—U.S. House Energy and Commerce (E&C) Chair Frank Pallone this morning introduced a significantly slimmed-down version of H.R. 3, the drug pricing bill that the House passed during the last session of Congress

Read More »

Congress Passes Bills Aimed at Boosting Generics and Biosimilars

Congress has sent President Biden two bills to boost generic and biosimilar drugs. Generics are exact copies and biosimilars are highly similar to original brand products. | Shutterstock

UPDATED Monday, April 26, 2021, 9:00 a.m. EDT—President Biden signed the two bills into law on April 23.

The U.S. House of Representatives passed two bills last week intended to reduce the overall costs of medications by boosting competition for

Read More »

BREAKING: Key GOP U.S. Senator Presses HHS Deputy Secretary Nominee to Take Action on 340B

Andrea Palm, President Biden's pick to be HHS Deputy Secretary, indicated in response to a question during her confirmation hearing today that "there are things [HHS] can and needs to be doing" about 340B hospitals' complaints about drugs manufacturers and PBMs.

Andrea Palm, President Biden’s pick to be the number two official at the U.S. Health and Human Services Department (HHS), pledged during her U.S. Senate confirmation hearing this morning to make sure that the 340B program “is working as it

Read More »

Could Concern About Hospital Price Transparency Boost Push for More Hospital 340B Transparency?

Bipartisan concern in Congress about hospitals' compliance with new price transparency rules might enhearten drugmakers and others who want to impose reporting requirements on 340B hospitals. | Shutterstock

The bipartisan leaders of the U.S. House Energy and Commerce (E&C) Committee and its Health Subcommittee wrote to U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week asking him to enforce “full compliance” with the Trump administration’s hospital

Read More »

340B Could Come Up During Congressional Hearings Thursday

From left to right, HHS Secretary Xavier Becerra, CMS Administrator nominee Chiquita Brooks-LaSure, and HHS Deputy Secretary nominee Andrea Palm will all be on Capitol Hill on Thursday.

The U.S. Senate Finance Committee is scheduled to hold a hearing Thursday morning on President Biden’s nominations of Chiquita Brooks-LaSure to run the U.S. Centers for Medicare & Medicaid Services, and Andrea Palm to be U.S. Health and Human Services

Read More »

MACPAC Backs Medicaid Change That Could Lower Some 340B Prices

Raising the Medicaid rebate percentage and inflation penalty on accelerated-approval drugs, as the Medicaid and CHIP Payment and Access Commission (MACPAC) recommends, could lead to lower 340B ceiling prices on those drugs.

Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need.

If Congress follows the Medicaid and CHIP

Read More »

NY State 340B Providers Get More Time to Challenge Reimbursement Change

New York lawmakers and Gov. Andrew Cuomo agreed on budget legislation this week that will delay a Medicaid drug benefit transfer opposed by 340B entities for two years.

New York state lawmakers and Gov. Andrew Cuomo (D) agreed this week to postpone transferring Medicaid managed care prescription drug  benefits to Medicaid fee for service (FFS) for two years, temporarily averting a significant financial loss to 340B covered entities.

Read More »

AHA Warns MedPAC its Recommendations Would Harm 340B Hospitals

Hospitals say that Medicare Part B drug reimbursement changes that MedPAC endorsed last week would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018. | Shutterstock

Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.

The Medicare Payment Advisory Commission (MedPAC)

Read More »

340B Gets Cameo Role in Senate Hearing on Government Drug Price Negotiation

Harvard Medical School professor Dr. Aaron Kesselheim told a Senate subcommittee yesterday, “There’s no doubt the fact that 340B pricing is among the best prices we offer for certain high-cost drugs.”

The Senate committee with direct jurisdiction over the 340B program held its first drug pricing hearing of the 117th Congress Tuesday. It held the session amid signs that House Democrats want to add language to let Medicare negotiate drug prices

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live